View Future GrowthKMPHARMACEUTICALLtd 過去の業績過去 基準チェック /06KMPHARMACEUTICALLtdの収益は年間平均-35.6%の割合で減少していますが、 Personal Products業界の収益は年間 増加しています。収益は年間20.2% 9.1%割合で 減少しています。主要情報-35.57%収益成長率-34.90%EPS成長率Personal Products 業界の成長3.77%収益成長率-9.13%株主資本利益率-14.50%ネット・マージン-24.29%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.すべての更新を表示Recent updatesお知らせ • Jul 29KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces an Equity Buyback for 207,612 shares, for KRW 300 million.KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces a share repurchase program. Under the program, the company will repurchase up to207,612 for KRW 300 million worth of its shares. The shares will be repurchased at a price of KRW 1,445 per share. The purpose of the program is enhancing shareholder value and stabilizing stock prices. The program will expire on September 10, 2026. As of July 27, 2026, the company had no shares in treasury within scope available for dividend or under other acquisitions.お知らせ • Jul 16KMPHARMACEUTICAL Co.,Ltd. announced that it expects to receive KRW 999.999765 million in fundingKMPHARMACEUTICAL Co.,Ltd. announces a private placement to issue 908,265 Common Shares at an issue price of KRW 1,101 for an aggregate gross proceeds of KRW 999,999,765 on July 14, 2026. The transaction involves participation of BAIK BRIAN SEUNG WON for 908,265 Common Shares. The securities under this transaction is subject to one year mandatory lockup. The transaction is expected to close on July 24, 2026.Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.New Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).お知らせ • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.お知らせ • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea分析記事 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).お知らせ • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South KoreaNew Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.収支内訳KMPHARMACEUTICALLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A225430 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2616,379-3,9786,20289931 Dec 2515,990-3,9685,97594430 Sep 2515,093-4,6786,04483730 Jun 2514,015-4,6125,80271931 Mar 2514,088-4,8816,40762831 Dec 2414,475-4,5736,39256030 Sep 2414,545-3,6486,07247830 Jun 2415,295-3,2086,05139731 Mar 2417,095-1,8175,39133731 Dec 2317,770-1,3205,23029830 Sep 2317,580-2,7766,87132130 Jun 2317,711-3,2666,43437631 Mar 2316,044-3,9056,05541431 Dec 2215,631-3,9255,99645030 Sep 2218,805-1,8643,91749230 Jun 2220,000-1,2713,98747331 Mar 2222,043-6704,25244531 Dec 2122,705-6114,01440530 Sep 2121,335-2293,56132030 Jun 2121,164-153,78927731 Mar 2122,518734,01627231 Dec 2022,9284714,37130730 Sep 2022,844-5125,82637130 Jun 2023,443-5526,62530431 Mar 2021,326-6126,34942131 Dec 1920,338-9026,53436830 Sep 1919,7312335,64729130 Jun 1918,406-12,3194,48929131 Mar 1917,477-12,5614,53715831 Dec 1817,302-12,3303,81017830 Sep 1816,654-12,0043,26416131 Dec 1716,9151,7523,173100質の高い収益: A225430は現在利益が出ていません。利益率の向上: A225430は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A225430は利益が出ておらず、過去 5 年間で損失は年間35.6%の割合で増加しています。成長の加速: A225430の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A225430は利益が出ていないため、過去 1 年間の収益成長をPersonal Products業界 ( 20.6% ) と比較することは困難です。株主資本利益率高いROE: A225430は現在利益が出ていないため、自己資本利益率 ( -14.5% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/19 05:10終値2026/08/19 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KMPHARMACEUTICAL Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 29KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces an Equity Buyback for 207,612 shares, for KRW 300 million.KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces a share repurchase program. Under the program, the company will repurchase up to207,612 for KRW 300 million worth of its shares. The shares will be repurchased at a price of KRW 1,445 per share. The purpose of the program is enhancing shareholder value and stabilizing stock prices. The program will expire on September 10, 2026. As of July 27, 2026, the company had no shares in treasury within scope available for dividend or under other acquisitions.
お知らせ • Jul 16KMPHARMACEUTICAL Co.,Ltd. announced that it expects to receive KRW 999.999765 million in fundingKMPHARMACEUTICAL Co.,Ltd. announces a private placement to issue 908,265 Common Shares at an issue price of KRW 1,101 for an aggregate gross proceeds of KRW 999,999,765 on July 14, 2026. The transaction involves participation of BAIK BRIAN SEUNG WON for 908,265 Common Shares. The securities under this transaction is subject to one year mandatory lockup. The transaction is expected to close on July 24, 2026.
Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).
お知らせ • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.
お知らせ • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
分析記事 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).
New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).
New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).
お知らせ • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
New Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).
New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).
Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.